<DOC>
	<DOCNO>NCT00531401</DOCNO>
	<brief_summary>The purpose study determine whether Salirasib effective shrink prevent growth tumor associate non-small cell lung cancer patient newly diagnose recurrent disease .</brief_summary>
	<brief_title>Study Salirasib Treat Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Farnesylthiosalicylic acid</mesh_term>
	<mesh_term>Salicylates</mesh_term>
	<criteria>Age 18 old NonSmall Cell Lung Cancer amenable curative therapy surgery radiation Measurable disease Adenocarinoma lung , receive prior chemotherapy malignancy ≥ 15 pack year history smoking ; OR previously treat recurrent disease document KRAS mutation Last dose radiotherapy &gt; 3 week prior study entry recover acute toxicity associate prior therapy No history another malignancy past 5 year except treat nonmelanomatous skin cancer superficial bladder cancer carcinomainsitu cervix Karnofsky Performance status 70 great Body Weight &gt; 50 kg Life expectancy ≥ 3 month Serum Creatinine ≤2.0 mg/dL , total bilirubin ≤ 2.0 mg/dL , ALT AST ≤ 3x ULN , alkaline phosphatase ≤ 5x ULN , WBC &gt; 3000/mm³ , ANC ≥ 1500/mm³ , platelet ≥ 100,000/mm³ , hemoglobin ≥ 10g/dL . No coexist cardiac medical problem would limit compliance study Willing undergo blood sample pharmacokinetic analysis Negative pregnancy test , applicable Evidence active heart disease include myocardial infarction within previous 3 month Active infectious process Active central nervous system metastasis ( require increase dos corticosteroid prior month , know progress lesion ) Pregnant lactate Major surgery without full recovery major surgery within 3 week prior treatment start QTc Interval &gt; 470 msec Gastrointestinal tract disease result inability take absorb oral medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Non-Small-Cell Lung</keyword>
</DOC>